Total Payments
$47,452
2024 Payments
$1,069
Companies
8
Transactions
81
Payment Breakdown by Category
Consulting$37,330 (78.7%)
Travel$6,467 (13.6%)
Food & Beverage$2,325 (4.9%)
Research$1,283 (2.7%)
Gifts$47.00 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,330 | 8 | 78.7% |
| Travel and Lodging | $6,467 | 23 | 13.6% |
| Food and Beverage | $2,325 | 41 | 4.9% |
| Unspecified | $1,283 | 8 | 2.7% |
| Gift | $47.00 | 1 | 0.1% |
Payments by Type
General
$46,169
73 transactions
Research
$1,283
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $27,092 | 32 | $0 (2019) |
| US WorldMeds, LLC | $10,745 | 12 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $7,651 | 19 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,283 | 8 | $0 (2019) |
| LivaNova USA, Inc. | $499.82 | 4 | $0 (2019) |
| Janssen Research & Development, LLC | $129.81 | 4 | $0 (2018) |
| Allergan Inc. | $32.27 | 1 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $18.83 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,069 | 8 | Janssen Pharmaceuticals, Inc ($1,050) |
| 2020 | $2,250 | 4 | Janssen Pharmaceuticals, Inc ($2,250) |
| 2019 | $18,779 | 32 | Alkermes, Inc. ($7,500) |
| 2018 | $14,797 | 21 | Alkermes, Inc. ($9,035) |
| 2017 | $10,557 | 16 | Alkermes, Inc. ($10,557) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $47.49 | General |
| Category: Neuroscience | ||||||
| 11/16/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $31.66 | General |
| Category: Neuroscience | ||||||
| 11/16/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Neuroscience | ||||||
| 11/16/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $497.09 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $277.84 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $164.33 | General |
| Category: Neuroscience | ||||||
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: PSYCHIATRY | ||||||
| 02/28/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Neuroscience | ||||||
| 02/28/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Neuroscience | ||||||
| 02/28/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuroscience | ||||||
| 02/28/2020 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuroscience | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $186.19 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $126.79 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | Cash or cash equivalent | $80.36 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/05/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $537.75 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/05/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $126.79 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/05/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $125.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 09/21/2019 | LivaNova USA, Inc. | VNS Therapy (Device) | Travel and Lodging | In-kind items and services | $315.81 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/20/2019 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $69.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/20/2019 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/20/2019 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $55.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/08/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $3,030.00 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,283 | 8 |
About Dr. Danesh Alam, MD
Dr. Danesh Alam, MD is a Psychiatry healthcare provider based in Winfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043227200.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Danesh Alam, MD has received a total of $47,452 in payments from pharmaceutical and medical device companies, with $1,069 received in 2024. These payments were reported across 81 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($37,330).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location Winfield, IL
- Active Since 08/01/2006
- Last Updated 10/26/2022
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1043227200
Products in Payments
- Lucemyra/Lofexidine (Drug) $10,745
- Vivitrol 380 mg (Drug) $10,722
- SPRAVATO (Drug) $7,651
- VIVITROL (Drug) $7,500
- REXULTI (Drug) $1,283
- VNS Therapy (Device) $499.82
- ABILIFY MAINTENA (Drug) $18.83
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Winfield
Gautam Sharma, M.d, M.D
Psychiatry — Payments: $6,882
Psychiatry $6,882
Saima Sabah, Md, MD
Psychiatry — Payments: $1,697
Psychiatry $1,697
Dr. Anoop Vermani, M.d, M.D
Psychiatry — Payments: $1,313
Psychiatry $1,313
Dr. Muhammad Husain, Md, MD
Psychiatry — Payments: $750.13
Psychiatry $750.13
Dr. Jamie Pacis
Psychiatry — Payments: $402.57
Psychiatry $402.57
Bojan Slavnic, D.o, D.O
Psychiatry — Payments: $402.10
Psychiatry $402.10